Usynova

News

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront.

News

Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.